Theravance Biopharma Reports Q2 2026 Financial Results

What Happened
Theravance Biopharma, Inc. announced its financial results and provided a business update on August 10, 2026, for the quarter ended June 30, 2026. The company issued a press release conveying these quarterly results and related commentary; that press release is furnished as Exhibit 99.1 to the Current Report on Form 8-K.

Key Details

• Report date: August 10, 2026 (press release issued and 8-K filed under Item 2.02).
• Reporting period: quarter ended June 30, 2026 (quarterly results/financial condition disclosed).
• Exhibit: Press release furnished as Exhibit 99.1 to the Form 8-K.
• Regulatory note: The press release information is furnished (not “filed”) under Item 9.01 and therefore is not subject to Section 18 liability or automatically incorporated by reference in other filings.

Why It Matters
This 8-K signals that Theravance has released its latest quarterly earnings and a corporate update—key information investors use to assess recent revenue, expenses, cash position, and business progress. Retail investors should read the furnished press release (Exhibit 99.1) for the specific financial metrics (revenue, net income/loss, EPS, guidance or operational highlights) and follow any supplementary filings or investor materials the company posts for full context.